All lanes : Anti-SREBP1c (phospho S372) antibody (ab140483) at 1 µg/mlLane 1 : Human Fetal Liver Tissue LysateLane 2 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell LysateLane 3 : Human Fetal Liver Tissue Lysate with Immunising peptide at 1 µg/mlLane 4 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Immunising peptide at 1 µg/mlLane 5 : Human Fetal Liver Tissue Lysate with Control peptide at 1 µg/mlLane 6 : HepG2 (Human hepatocellular liver carcinoma cell line) Whole Cell Lysate with Control peptide at 1 µg/mlLysates/proteins at 10 µg per lane.SecondaryGoat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/10000 dilutiondeveloped using the ECL techniquePerformed under reducing conditions.
ab140483 was tested using an Indirect ELISA approach. The wells were coated with peptide (1µg/ml at 100µl/well) overnight at 4°C, followed by a 5% BSA blocking step for 1 hour at room temperature. The primary Ab was then added at a dilution range of 1- 0.00025µg/ml (100µl/well) for 1hr at room temperature. A HRP-conjugated anti-rabbit IgG (heavy and light chain) was used as a secondary antibody at 1:20,000 dilution for 1hr at room temperature.